Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP320919.RA69a4c-z6ml58PO9VhgT6QBaOjyaocrLCefy8AEEcv1Q130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP320919.RA69a4c-z6ml58PO9VhgT6QBaOjyaocrLCefy8AEEcv1Q130_assertion type Assertion NP320919.RA69a4c-z6ml58PO9VhgT6QBaOjyaocrLCefy8AEEcv1Q130_head.
- NP320919.RA69a4c-z6ml58PO9VhgT6QBaOjyaocrLCefy8AEEcv1Q130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP320919.RA69a4c-z6ml58PO9VhgT6QBaOjyaocrLCefy8AEEcv1Q130_provenance.
- NP320919.RA69a4c-z6ml58PO9VhgT6QBaOjyaocrLCefy8AEEcv1Q130_assertion evidence source_evidence_literature NP320919.RA69a4c-z6ml58PO9VhgT6QBaOjyaocrLCefy8AEEcv1Q130_provenance.
- NP320919.RA69a4c-z6ml58PO9VhgT6QBaOjyaocrLCefy8AEEcv1Q130_assertion SIO_000772 23847380 NP320919.RA69a4c-z6ml58PO9VhgT6QBaOjyaocrLCefy8AEEcv1Q130_provenance.
- NP320919.RA69a4c-z6ml58PO9VhgT6QBaOjyaocrLCefy8AEEcv1Q130_assertion wasDerivedFrom befree-20150227 NP320919.RA69a4c-z6ml58PO9VhgT6QBaOjyaocrLCefy8AEEcv1Q130_provenance.
- NP320919.RA69a4c-z6ml58PO9VhgT6QBaOjyaocrLCefy8AEEcv1Q130_assertion wasGeneratedBy ECO_0000203 NP320919.RA69a4c-z6ml58PO9VhgT6QBaOjyaocrLCefy8AEEcv1Q130_provenance.